StrataCTX® as a Steroid Sparing Device
NCT: NCT04087629 · RECRUITING
Brief Summary
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.
Frequently Asked Questions
What is StrataCTX® as a Steroid Sparing Device?
StrataCTX® as a Steroid Sparing Device is a clinical trial registered under NCT04087629. Current status: RECRUITING.
What is the status of NCT04087629?
The current status of NCT04087629 (StrataCTX® as a Steroid Sparing Device) is: RECRUITING.
When did StrataCTX® as a Steroid Sparing Device start?
StrataCTX® as a Steroid Sparing Device started on 2021-07-07.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.